Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 57
2021 78
2022 94
2023 51
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

263 results

Results by year

Filters applied: . Clear all
Page 1
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.
Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, Ferrajolo C, Moretti U, Poluzzi E, Raschi E, Ravaldi C, Reno C, Tuccori M, Vannacci A, Zanoni G, Trifirò G; Ilmiovaccino COVID19 collaborating group. Luxi N, et al. Drug Saf. 2021 Dec;44(12):1247-1269. doi: 10.1007/s40264-021-01131-6. Epub 2021 Nov 5. Drug Saf. 2021. PMID: 34739716 Free PMC article. Review.
To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vax …
To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent …
COVID-19 Outbreak: An Overview.
Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, Sagnelli C, Bianchi M, Bernardini S, Ciccozzi M. Ciotti M, et al. Chemotherapy. 2019;64(5-6):215-223. doi: 10.1159/000507423. Epub 2020 Apr 7. Chemotherapy. 2019. PMID: 32259829 Free PMC article. Review.
MN908947) and made publicly available to the scientific community. This novel coronavirus was provisionally named 2019-nCoV, now SARS-CoV-2 according to the Coronavirus Study Group of the International Committee on Taxonomy …
MN908947) and made publicly available to the scientific community. This novel coronavirus was provisionally named 2019-nCoV …
Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group.
Ursini F, Ruscitti P, Addimanda O, Foti R, Raimondo V, Murdaca G, Caira V, Pigatto E, Cuomo G, Lo Gullo A, Cavazzana I, Campochiaro C, Naclerio C, De Angelis R, Ciaffi J, Mancarella L, Brusi V, Marchetti E, Motta F, Visentini M, Lorusso S, De Santis M, De Luca G, Massaro L, Olivo D, Pellegrini R, Francioso F, Luppino J, Di Cola I, Foti R, Varcasia G, Caso F, Reta M, Dagna L, Selmi C, Iagnocco A, Giacomelli R, Iannone F, Ferri C. Ursini F, et al. RMD Open. 2023 Jun;9(2):e003022. doi: 10.1136/rmdopen-2023-003022. RMD Open. 2023. PMID: 37328292 Free PMC article.
METHODS: Consecutive cases of IRD encountered during a 12-month period and satisfying one of the following inclusion criteria: (a) onset of the rheumatic manifestations within 4 weeks from SARS-CoV-2 infection or (b) onset of the rheumatic manifestations with …
METHODS: Consecutive cases of IRD encountered during a 12-month period and satisfying one of the following inclusion criteria: (a) onset of …
Drug-utilisation profiles and COVID-19.
Orlando V, Coscioni E, Guarino I, Mucherino S, Perrella A, Trama U, Limongelli G, Menditto E. Orlando V, et al. Sci Rep. 2021 Apr 26;11(1):8913. doi: 10.1038/s41598-021-88398-y. Sci Rep. 2021. PMID: 33903671 Free PMC article.
Coronavirus disease 2019 (COVID-19) has substantially challenged healthcare systems worldwide. ...We aimed to discover the prevalence of drug utilisation (monotherapy and polytherapy) in COVID-19 versus non-COVID-19 patients in Cam …
Coronavirus disease 2019 (COVID-19) has substantially challenged healthcare systems worldwide. ...We aimed to discover …
Anticoagulant treatment in COVID-19: a narrative review.
Carfora V, Spiniello G, Ricciolino R, Di Mauro M, Migliaccio MG, Mottola FF, Verde N, Coppola N; Vanvitelli COVID-19 group. Carfora V, et al. J Thromb Thrombolysis. 2021 Apr;51(3):642-648. doi: 10.1007/s11239-020-02242-0. J Thromb Thrombolysis. 2021. PMID: 32809158 Free PMC article. Review.
The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family. ...Therefore, the correct unde …
The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute respiratory syndrome …
Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.
Vitiello A, Ferrara F, Zovi A, Trama U, Boccellino M. Vitiello A, et al. J Reprod Immunol. 2022 Jun;151:103630. doi: 10.1016/j.jri.2022.103630. Epub 2022 Apr 21. J Reprod Immunol. 2022. PMID: 35483212 Free PMC article. Review.
The global pandemic of COVID-19 is currently ongoing. Clinical evidence shows that specific population groups such as the elderly, individuals with comorbidities, and pregnant women may be at increased risk for infection and serious complications. ...G …
The global pandemic of COVID-19 is currently ongoing. Clinical evidence shows that specific population groups su …
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase.
Ferri C, Raimondo V, Giuggioli D, Gragnani L, Lorini S, Dagna L, Bosello SL, Foti R, Riccieri V, Guiducci S, Cuomo G, Tavoni A, De Angelis R, Cacciapaglia F, Zanatta E, Cozzi F, Murdaca G, Cavazzana I, Romeo N, Codullo V, Pellegrini R, Varcasia G, De Santis M, Selmi C, Abignano G, Caminiti M, L'Andolina M, Olivo D, Lubrano E, Spinella A, Lumetti F, De Luca G, Ruscitti P, Urraro T, Visentini M, Bellando-Randone S, Visalli E, Testa D, Sciascia G, Masini F, Pellegrino G, Saccon F, Balestri E, Elia G, Ferrari SM, Tonutti A, Dall'Ara F, Pagano Mariano G, Pettiti G, Zanframundo G, Brittelli R, Aiello V, Dal Bosco Y, Foti R, Di Cola I, Scorpiniti D, Fusaro E, Ferrari T, Gigliotti P, Campochiaro C, Francioso F, Iandoli C, Caira V, Zignego AL, D'Angelo S, Franceschini F, Matucci-Cerinic M, Giacomelli R, Doria A, Santini SA, Fallahi P, Iannone F, Antonelli A; COVID-19 & ASD Italian Study Group. Ferri C, et al. J Transl Autoimmun. 2023 Oct 9;7:100212. doi: 10.1016/j.jtauto.2023.100212. eCollection 2023 Dec. J Transl Autoimmun. 2023. PMID: 37854035 Free PMC article.
The following parameters were carefully evaluated: i. demographic, clinical, serological, and therapeutical features; ii. prevalence and severity of COVID-19; and iii. safety, immunogenicity, and efficacy of COVID-19 vaccines. RESULTS: The preva …
The following parameters were carefully evaluated: i. demographic, clinical, serological, and therapeutical features; ii. prevalence and sev …
Implications of ABO blood group in hypertensive patients with covid-19.
Sardu C, Marfella R, Maggi P, Messina V, Cirillo P, Codella V, Gambardella J, Sardu A, Gatta G, Santulli G, Paolisso G. Sardu C, et al. Res Sq [Preprint]. 2020 Aug 12:rs.3.rs-28258. doi: 10.21203/rs.3.rs-28258/v2. Res Sq. 2020. PMID: 32818207 Free PMC article. Updated. Preprint.
Background: Hypertension is the most frequent co-morbidity in patients with covid-19 infection, and we might speculate that a specific blood group could play a key role in the clinical outcome of hypertensive patients with covid-19. ...At the mu …
Background: Hypertension is the most frequent co-morbidity in patients with covid-19 infection, and we might speculate that a …
Implications of AB0 blood group in hypertensive patients with covid-19.
Sardu C, Marfella R, Maggi P, Messina V, Cirillo P, Codella V, Gambardella J, Sardu A, Gatta G, Santulli G, Paolisso G. Sardu C, et al. BMC Cardiovasc Disord. 2020 Aug 14;20(1):373. doi: 10.1186/s12872-020-01658-z. BMC Cardiovasc Disord. 2020. PMID: 32799852 Free PMC article.
BACKGROUND: Hypertension is the most frequent co-morbidity in patients with covid-19 infection, and we might speculate that a specific blood group could play a key role in the clinical outcome of hypertensive patients with covid-19. ...At the mu …
BACKGROUND: Hypertension is the most frequent co-morbidity in patients with covid-19 infection, and we might speculate that a …
Clinical Differences between COVID-19 and a COVID-Like Syndrome.
Di Micco P, Camporese G, Russo V, Cardillo G, Imbalzano E, Tufano A, Bernardi E, Fontanella A. Di Micco P, et al. J Clin Med. 2021 Jun 7;10(11):2519. doi: 10.3390/jcm10112519. J Clin Med. 2021. PMID: 34200168 Free PMC article.
COVID-19 is an infection due to SARS-CoV-2; this virus has been identified as the cause of the present pandemic. ...Ground-glass opacities with pneumonia are the most common and dangerous presentations of the COVID-19 disease, and …
COVID-19 is an infection due to SARS-CoV-2; this virus has been identified as the cause of the present pa …
263 results